Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844566 | 1.00 | IDO1 (0.57) | IDO1PAMMAOBMAOAMMP1 | |
| SCHEMBL3793245 | 0.81 | APP (0.42) | IDO1MAOBMAOA | |
| SCHEMBL5539321 | 0.81 | IDO1 (0.44) | IDO1PAMHTR2A | |
| SCHEMBL5547894 | 0.81 | GRIK1 (0.39) | IDO1MAOBMAOA | |
| SCHEMBL5536696 | 0.81 | RELA (0.41) | IDO1MAOB | |
| SCHEMBL5544293 | 0.81 | CYP1A2 (0.41) | IDO1MAOB | |
| SCHEMBL5547901 | 0.81 | GRIK1 (0.39) | IDO1MAOBMAOA | |
| SCHEMBL5544290 | 0.81 | CYP1A2 (0.41) | IDO1MAOB | |
| SCHEMBL5541069 | 0.81 | HSD11B1 (0.41) | IDO1HTR2A | |
| SCHEMBL5541067 | 0.81 | HSD11B1 (0.41) | IDO1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671798-B | Green synthesis method of antiviral drug intermediate | 上海皓元医药股份有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-114671798-A | Green synthesis method of antiviral drug intermediate | 上海皓元医药股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| EP-3053944-B1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | SHINETSU CHEMICAL CO (JP) | 2021-10-06 | — | — | EP | claimed |
| EP-2061450-B1 | METHODS OF MODULATING CELL PROLIFERATION AND CYST FORMATION IN POLYCYSTIC KIDNEY AND LIVER DISEASES | MEDICAL COLLEGE WISCONSIN INC (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2012145932-A1 | A NOVEL PROCESS FOR THE PREPARATION OF PERAMIVIR AND INTERMEDIATES THEREOF | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2012-11-01 | — | — | WO | claimed |
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | FUTURECHEM CO., LTD. (KR) | 2012-08-23 | — | — | US | claimed |
| WO-2007054965-A2 | PROCESS FOR PREPARATION OF TETRAZOLES FROM AROMATIC CYANO DERIVATIVES | ALEMBIC LIMITED (IN) | 2007-05-18 | — | — | WO | claimed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | claimed |
| EP-1690863-A1 | NOVEL CONDENSED IMIDAZOLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-16 | — | — | EP | claimed |
| US-7078400-B2 | 20-HETE synthase inhibitor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-18 | — | — | US | claimed |
| EP-0340245-B1 | SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS | GRUPPO LEPETIT S.p.A. (IT) | 1992-08-19 | — | — | EP | claimed |
| WO-1992010516-A1 | 38-DECARBOXY-38-HYDROXYMETHYL DERIVATIVES OF TEICOPLANIN ANTIBIOTICS, AND A PROCESS FOR PREPARING THEM | GRUPPO LEPETIT S.P.A. (IT) | 1992-06-25 | — | — | WO | claimed |
| EP-0218099-B1 | AMIDES OF TEICOPLANIN COMPOUNDS | GRUPPO LEPETIT S.p.A. (IT) | 1991-12-11 | — | — | EP | claimed |
| EP-0170280-B1 | NOVEL INTERMEDIATES AND PROCESS FOR THE PREPARATION OF 3-ACYLAMINO-1-HYDROXY-2-AZETIDINONES | E.R. Squibb & Sons, Inc. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0340245-A1 | SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS. | LEPETIT SPA (IT) | 1989-11-08 | — | — | EP | claimed |
| WO-1988006600-A1 | SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS | GRUPPO LEPETIT S.P.A. (IT) | 1988-09-07 | — | — | WO | claimed |
| EP-0218099-A2 | Amides of teicoplanin compounds | GRUPPO LEPETIT S.p.A. (IT) | 1987-04-15 | — | — | EP | claimed |
| EP-0215739-A1 | Synthesis of beta-lactam compounds | CIBA-GEIGY AG (CH) | 1987-03-25 | — | — | EP | claimed |
| US-4581170-A | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-04-08 | — | — | US | claimed |
| EP-0170280-A1 | Novel intermediates and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones | E.R. Squibb & Sons, Inc. (US) | 1986-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | IDO1 817/4885PAM 4032/4885MAOB 802/4885 |
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | APP, FABP7, SLC3A2 | IDO1 3642/4885PAM 1300/4885MAOB 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.